2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the …
2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Guidelines for the management of acute coronary syndromes Developed by the task force on …
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
I Lingvay, J Deanfield, SE Kahn, PE Weeke… - Diabetes …, 2024 - diabetesjournals.org
OBJECTIVE To evaluate the cardiovascular effects of semaglutide by baseline glycated
hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects …
hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects …
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup …
SE Inzucchi, BL Claggett, M Vaduganathan… - The Lancet Diabetes & …, 2022 - thelancet.com
Background Type 2 diabetes and prediabetes are risk factors for heart failure and adverse
heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with …
heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with …
Variation in secondary prevention of coronary heart disease: the INTERASPIRE study
Background and Aims INTERASPIRE is an international study of coronary heart disease
(CHD) patients, designed to measure if guideline standards for secondary prevention and …
(CHD) patients, designed to measure if guideline standards for secondary prevention and …
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline …
In recent years, several novel agents have become available to treat individuals with type 2
diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide …
diabetes (T2D), such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i), tirzepatide …
Comprehensive care models for cardiometabolic disease
Abstract Purpose of Review The high burden of cardiovascular disease and the
simultaneous obesity pandemic is placing an extraordinary strain on the health care system …
simultaneous obesity pandemic is placing an extraordinary strain on the health care system …
Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE risk model: results from a prospective study in 27 countries in the WHO …
D De Bacquer, P Ueda, Ž Reiner… - European Journal of …, 2022 - academic.oup.com
Aims Most patients with established atherosclerotic cardiovascular disease (CVD) are at
very high risk for developing recurrent events. Since this risk varies a lot between patients …
very high risk for developing recurrent events. Since this risk varies a lot between patients …
Carbohydrate intake prior to oral glucose tolerance testing
KR Klein, CP Walker, AL McFerren… - Journal of the …, 2021 - academic.oup.com
With the emergence of glycated hemoglobin as a diagnostic test for diabetes, oral glucose
tolerance tests (OGTTs) have become rare in endocrinology practice. As they have moved …
tolerance tests (OGTTs) have become rare in endocrinology practice. As they have moved …
Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and …
KH Mak, E Vidal-Petiot, R Young… - European journal of …, 2021 - academic.oup.com
Background In contrast with the setting of acute myocardial infarction, there are limited data
regarding the impact of diabetes mellitus on clinical outcomes in contemporary cohorts of …
regarding the impact of diabetes mellitus on clinical outcomes in contemporary cohorts of …